Harry Simeonidis Net Worth

Mr. Harry Simeonidis biography

Harry Simeonidis is the Pres of Asia Pacific - Sales & Marketing at GBS.

What is the salary of Mr Simeonidis?

As the Pres of Asia Pacific - Sales & Marketing of GBS, the total compensation of Mr Simeonidis at GBS is $302,599. There are no executives at GBS getting paid more.

How old is Mr Simeonidis?

Mr Simeonidis is 53, he's been the Pres of Asia Pacific - Sales & Marketing of GBS since . There are 3 older and 1 younger executives at GBS. The oldest executive at GBS Inc. is Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D., 64, who is the Interim CEO & Chairman.

What's Mr Simeonidis's mailing address?

Harry's mailing address filed with the SEC is C/O GBS INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK, NY, 10019.

Insiders trading at GBS

Over the last 4 years, insiders at GBS have traded over $6,891,194 worth of GBS stock and bought 51,106 units worth $85,007 . The most active insiders traders include Science Biosensor Diagnosti..., Spiro Kevin Sakiris, and Tom Parmakellis. On average, GBS executives and independent directors trade stock every 12 days with the average trade being worth of $51,467. The most recent stock trade was executed by Spiro Kevin Sakiris on 22 June 2022, trading 5,000 units of GBS stock currently worth $3,250.

What does GBS do?

GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

GBS executives and stock owners

GBS executives and other stock owners filed with the SEC include:

• Harry Simeonidis,
  Pres of Asia Pacific - Sales & Marketing
• Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law,
  Chief Financial Officer
• Spiro Kevin Sakiris C.A., B.Bus, Dip Law, CA,
  Chief Financial Officer
• Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D.,
  Interim CEO & Chairman
• Joe Roxburgh,
  Non-Executive Director
• Steven Ross,
  Non-Executive Director
• Christopher Foulds,
  Non-Executive Director
• Graham Tuckwell,
  Non-Executive Chairman of the Board
• Alex Arzeno,
  VP of Investor Relations
• Victoria Gavrilenko,
  Operations Mang.
• Spiro Kevin Sakiris,
  Chief Financial Officer
• Harry Simeonidis,
  President
• Lawrence B Fisher,
  Director
• George Margelis,
  Director
• Jonathan Scott Hurd,
  Director
• Steven Constantine Boyages,
  Interim CEO and Chairperson
• Tom Parmakellis,
  Director
• Science Biosensor Diagnosti...,
  
• Victoria Gavrilenko,
  Director
• Christopher Towers,
  Director